article thumbnail

WHO trivalent recommendations will reshape global flu vaccine market: GlobalData

Express Pharma

With influenza season well underway, vaccination campaigns are in full force in the northern hemisphere. This will reshape the global influenza vaccine market for the upcoming seasons, says GlobalData. Kurdach continues, “When the actual composition of vaccines will revert to trivalent formulations remains another question.

article thumbnail

Losing ground in COVID-19 vaccine race, CanSino turns to Russia

pharmaphorum

Politicking between China and Canada threatened to slow down development of a coronavirus vaccine from CanSino Biologics, but the company says the project is back on track following regulatory approval to start trials in Russia. The post Losing ground in COVID-19 vaccine race, CanSino turns to Russia appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GSK Sues Pfizer for Patent Infringement over RSV Vaccine

Big Molecule Watch

alleging that Pfizer’s respiratory syncytial virus (“RSV”) vaccine ABRYSVO infringes four U.S. patents covering GSK’s rival RSV vaccine, AVREXY. 8,563,002, 11,261,239, 11,629,181, and 11,655,284, as claiming inventions relating to compositions used in RSV vaccines, and methods for preparing those compositions. Patent Nos.

article thumbnail

The imperative of fridge-free vaccines

European Pharmaceutical Review

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111
article thumbnail

GlobalData tracks 40 yrs of innovation in USFDA review designations

Express Pharma

This period included the implementation of novel designation types: qualified infectious disease product designation (in 2012), breakthrough therapy (2013), rare pediatric drug designation (2014), and regenerative medicine advanced therapy designation (2017). Over this period, annual designations awarded by the FDA increased almost four-fold.

Vaccines 104
article thumbnail

Race to the finish: pharma edges closer to approval with RSV vaccines

Pharmaceutical Technology

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

article thumbnail

Campaigners challenge NHS England’s latest plan to share patient data

pharmaphorum

The government’s last attempt to shake up patient data-sharing – 2013’s Care.data scheme – suffered from a number of false starts and was eventually shut down in 2016. People can opt out of the scheme by filling in a form and taking it to their GP before 23 June, but campaigners say this has not been communicated effectively.